We compared the clinical value of "Amerlex" (Amersham International) and "Pre-release Coat-A-Count" (Diagnostic Products Corp.) radioimmunoassay kits for free triiodothyronine with that of triiodothyronine, triiodothyronine/thyroxin-binding globulin ratio, and free triiodothyronine index in patients with thyroid disease, pregnant women, oral contraceptive users, thyroxin-binding globulin-deficient subjects, and patients receiving phenytoin. Assay of free triiodothyronine in hyperthyroidism provided diagnostic information similar to that from the indirect indices, whereas the free triiodothyronine index was the most sensitive index of hypothyroidism. With respect to diagnostic value, free triiodothyronine assay was comparable with the free triiodothyronine index and superior to triiodothyronine assay and the triiodothyronine/thyroxin-binding globulin ratio in correcting for alterations in thyroid-hormone binding capacity. In neither kit for free triiodothyronine was the equilibrium between bound and free hormone significantly disturbed during assay. Overall, as a diagnostic index of thyroid status, free triiodothyronine is as good as the free triiodothyronine index and better than either triiodothyronine or the triiodothyronine/thyroxin-binding globulin ratio.
The performance characteristics and diagnostic value of a monoclonal antibody-based radioimmunoassay for serum total thyroxine (Mallinckrodt) are described. Between-batch precision (coefficient of Variation) was 10.4% at 87 nmol/1 and 3.3% at 185 nmolA Scatchard analysis revealed a linear plot with a K a of 5.4 x 10 8 1/mol. \ Sensitivity was 4.5 nmol/1 of thyroxine. An association study showed that the assay reached equilibrium well within the specified incubation time. Cross-reaction of triiodothyronine and reverse triiodothyronine in the assay was 0.6% and 25.0% respectively. Analytical recovery was 91-110%. Linearity was well demonstrated but dilutions of a high concentration of thyroxine in serum did not parallel the Standard curve. The correlation coefficient for comparison with a polyclonal antibody assay was 0.95 for 83 patients. The diagnostic accuracy of the monoclonal antibody assay was adequate for most patients with thyroid disease, pregnant women, oral contraceptive users and subjects on thyroxine-replacement therapy. Measurement of total thyroxine by a monoclonal antibody-based method shows no definite advantage over the conventional polyclonal antibody assay. Erfahrungen in Laboratorium undKlinik mit einem Radioimmunassay für das gesamte Thyroxin im Serum auf der Grundlage eines monoklonalen Antikörpers Zusammenfassung: Die Charäkteristika der Durchführung und der diagnostische Wert eines Radioimmunassay mit monoklonalem Antikörper für das gesamte Thyroxin im Serum (Mallinckrodt) werden beschrieben. Die Impräzision von Serie zu Serie beträgt als Variationskoeffizient 10,4% bei 87 nmol/1 und 3,3% bei 185 nmol/1. Die Scatchard-Analyse ergab einen linearen Verlauf mit einem Wert für K a von 5,4 x 10 8 1/mol. Die Empfindlichkeit betrug 4,5 nmol/1 Thyroxin. Eine Bindungsstudie ergab, daß das Gleichgewicht innerhalb der angegebenen Inkubationszeit völlig erreicht wird. Die Kreuzreaktionen von Triiodthyronin und reverse Triiodthyronin betrugen 0,6 bzw. 25,0%. Die analytische Wiederfindung betrug 91-110%. Es konnte völlige Linearität nachgewiesen werden, jedoch ergaben Verdünnungen einer hohen Konzentration von Thyroxin im Serum keinen parallelen -Verlauf mit der Standardkurve. Der Korrelationskoeffizient für ein Vergleichsverfahren mit polykloiiälem Antikörper betrug r = 0,95 (n = 83 Patienten). Die diagnostische Richtigkeit des Radioimmunassay mit monoklonalem Antikörper war für die meisten Patienten mit Schilddrüsenerkrankungen, für Frauen* die orale Kontraceptiva einnahmen oder schwanger waren, sowie Personen unter Thyroxin^Substitution genügend. Die Bestimmung des Gesamtthyroxins unter Verwendung eines monoklonalen Antikörpers zeigt keinen deutlichen Vorteil gegenüber der Verwendung konventioneller polyklonaler Antikörper.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2025 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.